PEPGEN INC. Research and Development Expense
PEPGEN INC. (PEPG) reported Research and Development Expense of $12.52 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- PEPGEN INC. research and development expense for the quarter ending 2026-06-30 was $12.52M, a 31.91% decline year-over-year.
- PEPGEN INC. research and development expense for the quarter ending 2026-03-31 was $13.00M, a 48.76% decline year-over-year.
- PEPGEN INC. research and development expense for the quarter ending 2025-12-31 was $13.85M, a 26.95% decline year-over-year.
- PEPGEN INC. research and development expense for the quarter ending 2025-09-30 was $13.42M, a 24.26% decline year-over-year.
- PEPGEN INC. research and development expense for fiscal 2025 was $71.04M, a 7.11% decline from fiscal 2024.
- PEPGEN INC. research and development expense for fiscal 2024 was $76.48M, a 12.26% increase from fiscal 2023.
- PEPGEN INC. research and development expense for fiscal 2023 was $68.13M, a 25.98% increase from fiscal 2022.
- PEPGEN INC. research and development expense for fiscal 2022 was $54.08M, a 184.63% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.52M 10-Q · filed 2026-08-06 | $25.53M 10-Q · filed 2026-08-06 | $39.38M derived: sum of 3 quarters · filed 2026-08-06 | $52.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $13.00M 10-Q · filed 2026-05-12 | $26.86M derived: sum of 2 quarters · filed 2026-05-12 | $40.28M derived: sum of 3 quarters · filed 2026-05-12 | $58.67M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $13.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $27.27M derived: sum of 2 quarters · filed 2026-03-04 | $45.66M derived: sum of 3 quarters · filed 2026-08-06 | $71.04M 10-K · filed 2026-03-04 |
| 2025-09-30 | $13.42M 10-Q · filed 2025-11-12 | $31.81M derived: sum of 2 quarters · filed 2026-08-06 | $57.19M 10-Q · filed 2025-11-12 | $76.15M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $18.39M 10-Q · filed 2026-08-06 | $43.77M 10-Q · filed 2026-08-06 | $62.73M derived: sum of 3 quarters · filed 2026-08-06 | $80.45M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $25.38M 10-Q · filed 2026-05-12 | $44.34M derived: sum of 2 quarters · filed 2026-05-12 | $62.06M derived: sum of 3 quarters · filed 2026-05-12 | $87.12M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $18.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $36.68M derived: sum of 2 quarters · filed 2026-03-04 | $61.75M derived: sum of 3 quarters · filed 2026-03-04 | $76.48M 10-K · filed 2026-03-04 |
| 2024-09-30 | $17.72M 10-Q · filed 2025-11-12 | $42.78M derived: sum of 2 quarters · filed 2025-11-12 | $57.52M 10-Q · filed 2025-11-12 | $73.82M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $25.06M 10-Q · filed 2025-08-07 | $39.80M 10-Q · filed 2025-08-07 | $56.09M derived: sum of 3 quarters · filed 2025-08-07 | $76.64M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $14.73M 10-Q · filed 2025-05-08 | $31.03M derived: sum of 2 quarters · filed 2025-05-08 | $51.57M derived: sum of 3 quarters · filed 2025-05-08 | $68.50M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $16.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | $36.84M derived: sum of 2 quarters · filed 2025-02-24 | $53.77M derived: sum of 3 quarters · filed 2025-02-24 | $68.13M 10-K · filed 2025-02-24 |
| 2023-09-30 | $20.54M 10-Q · filed 2024-11-07 | $37.47M derived: sum of 2 quarters · filed 2024-11-07 | $51.83M 10-Q · filed 2024-11-07 | $64.99M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $16.93M 10-Q · filed 2024-08-08 | $31.29M 10-Q · filed 2024-08-08 | $44.45M derived: sum of 3 quarters · filed 2024-08-08 | $60.42M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $14.36M 10-Q · filed 2024-05-14 | $27.53M derived: sum of 2 quarters · filed 2024-05-14 | $43.49M derived: sum of 3 quarters · filed 2024-05-14 | $57.73M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $13.17M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-29 | $29.13M derived: sum of 2 quarters · filed 2024-03-29 | $43.37M derived: sum of 3 quarters · filed 2024-03-29 | $54.08M 10-K/A · filed 2024-03-29 |
| 2022-09-30 | $15.96M 10-Q · filed 2023-11-08 | $30.20M derived: sum of 2 quarters · filed 2023-11-08 | $40.91M 10-Q · filed 2023-11-08 | $45.45M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $14.24M 10-Q · filed 2023-08-08 | $24.95M 10-Q · filed 2023-08-08 | $29.49M derived: sum of 3 quarters · filed 2023-08-08 | $35.20M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $10.71M 10-Q · filed 2023-05-11 | $15.25M derived: sum of 2 quarters · filed 2023-05-11 | $20.96M derived: sum of 3 quarters · filed 2023-05-11 | $24.18M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $4.54M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $10.25M derived: sum of 2 quarters · filed 2023-03-23 | $13.47M derived: sum of 3 quarters · filed 2023-03-23 | $19.00M 10-K · filed 2023-03-23 |
| 2021-09-30 | $5.71M 10-Q · filed 2022-11-10 | $8.93M derived: sum of 2 quarters · filed 2022-11-10 | $14.46M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $3.22M 10-Q · filed 2022-08-12 | $8.75M 10-Q · filed 2022-08-12 | ||
| 2021-03-31 | $5.53M 10-Q · filed 2022-06-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |